Janssen Submits European Marketing Authorisation Application for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes(Mar 7, 2013)
BEERSE, March 7, 2013 ? Janssen-Cilag International NV (Janssen) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat adult patients with type 2 diabetes.....
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | European Medicines Agency (EMA) | Fortamet | Invokana | Marketing | Metformin | Pharmaceuticals